title: High risk of sensitization after failed islet transplantation.
abstract: Human Leukocyte Antigen (HLA) antibodies posttransplant have been associated with an increased risk of early graft failure in kidney transplants. Whether this also applies to islet transplantation is not clear. To achieve insulin independence after islet transplants multiple donor infusions may be required. Hence, islet transplant recipients are at risk of sensitization after transplantation. Islet transplant recipients were screened for HLA antibodies posttransplant by flow-based methods. A total of 98 patients were studied. Twenty-nine patients (31%) developed de novo donor specific antibodies (DSA) posttransplant. Twenty-three patients developed DSA while on immunosuppression (IS). Among recipients who have discontinued IS, 10/14 (71%) are broadly sensitized with panel reactive antibody (PRA) >or=50%. The risk of becoming broadly sensitized after transplant was 11/69 (16%) if the recipient was unsensitized prior to transplant. The majority of these antibodies have persisted over time. Appearance of HLA antibodies posttransplant is concerning, and the incidence rises abruptly in subjects weaned completely from IS. This may negatively impact the ability of these individuals to undergo further islet, pancreas or kidney transplantation and should be discussed upfront during evaluation of candidates for islet transplantation.
authors.affiliation: Department of Medicine, and Histocompatability Laboratory, University of Alberta, Capital Health, Edmonton, Alberta, Canada.
authors.forename: P M
authors.initials: PM
authors.lastname: Campbell
authors.forename: P A
authors.initials: PA
authors.lastname: Senior
authors.forename: A
authors.initials: A
authors.lastname: Salam
authors.forename: K
authors.initials: K
authors.lastname: Labranche
authors.forename: D L
authors.initials: DL
authors.lastname: Bigam
authors.forename: N M
authors.initials: NM
authors.lastname: Kneteman
authors.forename: S
authors.initials: S
authors.lastname: Imes
authors.forename: A
authors.initials: A
authors.lastname: Halpin
authors.forename: E A
authors.initials: EA
authors.lastname: Ryan
authors.forename: A M J
authors.initials: AM
authors.lastname: Shapiro
mesh_terms: D002096:C-Peptide / Q000172:deficiency; D006680:HLA Antigens / Q000276:immunology*; D015234:HLA-A Antigens / Q000276:immunology; D015235:HLA-B Antigens / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007114:Immunization; D016381:Islets of Langerhans Transplantation / Q000276:immunology* / Q000379:methods / Q000473:pathology; D007518:Isoantibodies / Q000097:blood; D013601:T-Lymphocytes / Q000276:immunology; D017211:Treatment Failure
chemical_list: D002096:C-Peptide; D006680:HLA Antigens; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006684:HLA-DR Antigens; D007518:Isoantibodies